Tavaborole, also known as AN-2690 (trade name Kerydin) is a topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed. Tavaborole began its Phase 3 trials in December 2010 and was approved in July 2014. Tavaborole inhibits an essential fungal enzyme, Leucyl-tRNA synthetase, or LeuRS, required for protein synthesis. The inhibition of protein synthesis leads to termination of cell growth and cell death, eliminating the fungal infection. No treatment-related systemic side effects were observed in any of its clinical trials.
Fungal Inhibitors Related Products:
Miconazole nitrate; AN2718; Terbinafine HCl; Liranaftate; Fenticonazole Nitrate; Amorolfine HCl; Tioconazole; Butoconazole nitrate; Cicloheximide; Luliconazole; Efinaconazole; Isavuconazole; Micafungin sodium; Micafungin; Butenafine hydrochloride